Search

First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies

Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function

FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*

Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim collaborate on first study to evaluate nintedanib in patients with fibrosing ILD following COVID-19 infection

A day of giving back at Pegasus Therapeutic Riding

Take a look at our volunteer day spent refreshing a farm committed to equine therapy.

Our Work with the Gates Foundation | COVID-19 | Boehringer Ingelheim US

With global life science companies, we are joining the COVID-19 Therapeutics Accelerator of the Bill & Melinda Gates Foundation to fight the pandemic.

200 employees make a difference with record-breaking volunteer efforts

Supporting People with Diabetes and Related Conditions in the Time of COVID-19

Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure

FDA Grants Fast Track to Jardiance® (empagliflozin) for CKD | Boehringer Ingelheim US

The FDA has granted Fast Track designation for JARDIANCE to reduce risk of disease progression and CV death with CKD. View ISI, PI & Med Guide.

New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment

FDA Mini-Sentinel Assessment Reinforces Safety Data of Pradaxa® (dabigatran etexilate mesylate)

Emmanuelle leads a team of scientists

Want to work for a company that allows you to grow your career? Emmanuelle talks about her job journey at Boehringer Ingelheim.

Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin

Boehringer Ingelheim and Lilly expand heart failure program for Jardiance with new exercise capacity trials

Boehringer Ingelheim Announces Jean-Michel Boers as U.S. Country Managing Director, President & CEO Effective August 1, 2020; Dr. Wolfgang Baiker to Retire

Pushing for Progress

Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis

Express Scripts Adds BI Products to Roster | BI US

Read more on Express Scripts adding the Spiriva Respimat, Spiriva Handihaler and Stiolto Respimat to their commercial national preferred formulary.

FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation

First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes

FDA Approves Stiolto® Respimat® sNDA to Add Data on COPD | BI US

FDA approves labeling for Stiolto® Respimat® (tiotropium bromide & olodaterol) with data showing reduction in COPD exacerbations. View ISI, PI & Med Guide.

Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation

Boehringer inhalers now available at $35 a month for eligible patients

Boehringer COPD and asthma inhalers now available at $35 a month for eligible patients

Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month

Boehringer Ingelheim cap out-of-pocket costs at $35 per month for eligible patients for all of the company’s inhaler products.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers